| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9297253b26452b98c7ca0b8e4002e23e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate |
2013-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2231f5d2d4d595e49161c5b6c555e855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2a866041717b920add5da923ffc9d2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4e4f448fa9d0604c1cdad7d1f274e86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c5e78c8fd9234362c933d4ee581eb8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4abcced3ee28ceaf081a9a4c80de300
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5873f327500c36a7bc969cb08dd39a75 |
| publicationDate |
2015-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201520222-A |
| titleOfInvention |
Composition for preventing mycoplasma infection |
| abstract |
The present invention provides a protein suitable as an active ingredient of a subunit vaccine against mycoplasma and a vaccine prepared therefrom. The aforementioned proteins have been experimentally confirmed to elicit an immune response of sufficient strength to prevent pigs from being infected with mycoplasma. The vaccine may contain one of the aforementioned proteins as an active ingredient or a form of a cocktail vaccine comprising two or more of the aforementioned proteins. The vaccine of the present invention is not only safer than conventional vaccines, but also has a comparable, even superior, immune effect. Further, the present invention has confirmed that a fusion partner suitable for producing a highly soluble protein of the foregoing can significantly save production costs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I606839-B |
| priorityDate |
2013-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |